Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome

Abstract

Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder for which there remains no gold standard treatment option. Here, we report a case of PTLDS in a female patient whose pain was refractory to treatment options such as radiofrequency ablation, vitamin infusion therapy, opioid analgesics, and other pharmacotherapies. The patient commenced an experimental intravenous ketamine infusion therapy at the Florida Spine Institute (Clearwater, FL, USA) and achieved relief from her chronic pain, an improved quality of life, reduced depression and suicidal ideation, and reduced opioid consumption.

DOI: 10.2147/IMCRJ.S137975

1 Figure or Table

Cite this paper

@inproceedings{Hanna2017EffectsOI, title={Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome}, author={Ashraf F. Hanna and Bishoy Abraham and Andrew I. Hanna and Adam J. Smith}, booktitle={International medical case reports journal}, year={2017} }